|
HK1052650A1
|
|
Methods for treating therapy-resistant tumors
|
|
EP1399467A2
|
|
Peptide deformylase activated prodrugs
|
|
WO02087500A2
|
|
Viral enzyme activated prototoxophores and use of same to treat viral infections
|
|
AU3645502A
|
|
Synergistic ecta compositions
|
|
AU7709301A
|
|
Methods for identifying therapeutic targets for treating infectious disease
|
|
AU5749001A
|
|
Improved beta-lactam antibiotics
|
|
IL151502D0
|
|
Anti-infective ecta
|
|
AU2451601A
|
|
Use of bvdu for inhibiting the growth of hyperproliferative cells
|
|
CN1391487A
|
|
Methods for treating therapy-resistant tumors
|
|
CA2378187A1
|
|
Methods for treating therapy-resistant tumors
|
|
US6683061B1
|
|
Enzyme catalyzed therapeutic activation
|
|
WO0107454A1
|
|
Enzyme catalyzed therapeutic activation
|
|
AU2464699A
|
|
Enzyme catalyzed therapeutic agents
|
|
EP1070140A1
|
|
Compositions and methods for treating cells having double minute dna
|
|
US6159706A
|
|
Application of enzyme prodrugs as anti-infective agents
|
|
WO9908110A1
|
|
Methods and compositions for overcoming resistance to biologic and chemotherapy
|
